The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin’s marketed products worldwide
hubergroup’s two newly added medical vans are dedicated to dental and eye care
Essex enriches and complements Emmes’ services
Women of all ages will get round-the-clock access to comprehensive treatment
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking
The one-year-long study was aimed to evaluate the efficacy of LDH's digital therapeutics platform
A funding to expand operations and provide better patient care
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
Subscribe To Our Newsletter & Stay Updated
